ArriVent BioPharma, Inc. (AVBP) – What Are Investment Firms Thinking About This Stock?

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $24.89.

A number of equities research analysts recently commented on the company. B. Riley Financial dropped their price objective on ArriVent BioPharma from $45.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 20th. Guggenheim increased their target price on ArriVent BioPharma from $18.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a report on Thursday. BTIG Research restated a “buy” rating and set a $29.00 target price on shares of ArriVent BioPharma in a research report on Friday, October 16th. Finally, JonesTrading decreased their target price on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th.

Read Our Latest Stock Analysis on AVBP

ArriVent BioPharma Stock Performance

AVBP traded down $0.06 during trading on Tuesday, reaching $13.01. 616,141 shares of the company’s stock were exchanged, compared to its average volume of 1,468,157. The company’s fifty day moving average price is $21.36 and its 200-day moving average price is $26.40. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83. The firm has a market capitalization of $672.88 million, a PE ratio of -3.61 and a beta of 1.66.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $5.00 million for the quarter, compared to the consensus estimate of $0.80 million. Research analysts forecast that ArriVent BioPharma will post -3.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. grew its holdings in shares of ArriVent BioPharma by 38.7% in the 3rd quarter. Alps Advisors Inc. now owns 65,315 shares of the company’s stock valued at $1,978,000 after buying an additional 18,241 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of ArriVent BioPharma in the 3rd quarter valued at $76,000. Profund Advisors LLC raised its stake in ArriVent BioPharma by 12.8% during the 3rd quarter. Profund Advisors LLC now owns 14,257 shares of the company’s stock worth $432,000 after buying an additional 1,614 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in ArriVent BioPharma by 21.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,997 shares of the company’s stock worth $266,000 after buying an additional 1,585 shares during the period. Finally, Moody Aldrich Partners LLC raised its stake in ArriVent BioPharma by 4.1% during the 3rd quarter. Moody Aldrich Partners LLC now owns 45,852 shares of the company’s stock worth $1,388,000 after buying an additional 1,808 shares during the period. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Featured Stories

Analyst Recommendations for ArriVent BioPharma (NASDAQ:AVBP)

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.